SCHEMBL5032061

SCHEMBL5032061

COCCOC(=O)c1cc(-c2ccc(NC(=O)c3c(F)cccc3F)cc2)cs1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.48
RAB9A P51151 3/20 0.45
DGAT1 O75907 1/20 0.43
JAK2 O60674 1/20 0.41
JAK1 P23458 1/20 0.41
TYK2 P29597 1/20 0.41
HTT P42858 1/20 0.41
NOD2 Q9HC29 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
IL2 P60568 5/20 0.41
TRPA1 O75762 2/20 0.39
TP53 P04637 3/20 0.39
MAPT P10636 1/20 0.39
KDR P35968 1/20 0.39
NPC1 O15118 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5030846 0.92 ABL1 (0.46) ABL1RAB9ADGAT1JAK2JAK1
SCHEMBL5033885 0.89 ABL1 (0.58) ABL1RAB9AJAK2JAK1TYK2
SCHEMBL4762631 0.76 IL2 (0.61) ABL1RAB9AIL2TP53MAPT
SCHEMBL5033848 0.72 IL2 (0.46) RAB9AMEN1KMT2AIL2TRPA1
SCHEMBL5029429 0.70 IL2 (0.61) RAB9AJAK2JAK1TYK2HTT
SCHEMBL2892068 0.70 IL2 (0.50) RAB9AJAK2JAK1TYK2HTT
SCHEMBL6875236 0.69 SMN1; SMN2 (0.56) ABL1HTTMEN1KMT2AMAPT
SCHEMBL4031637 0.69 RAB9A (0.65) RAB9AJAK2JAK1TYK2HTT
SCHEMBL5033817 0.69 RAB9A (0.50) RAB9AJAK2JAK1TYK2HTT
SCHEMBL5027355 0.69 DYRK1A (0.45) ABL1RAB9AJAK2JAK1TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1983831-A2 PHENYL AND PYRIDYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES Synta Pharmaceuticals Corporation (US) 2008-10-29 EP claimed
US-20070275960-A1 Phenyl and pyridyl compounds for inflammation and immune-related uses SYNTA PHARMACEUTICALS CORP. (US) 2007-11-29 US claimed
WO-2007087429-A2 PHENYL AND PYRIDYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2007-08-02 WO claimed
EP-1983831-A2 PHENYL AND PYRIDYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES Synta Pharmaceuticals Corporation (US) 2008-10-29 EP disclosed
US-20070275960-A1 Phenyl and pyridyl compounds for inflammation and immune-related uses SYNTA PHARMACEUTICALS CORP. (US) 2007-11-29 US disclosed
US-20070275960-A1 Phenyl and pyridyl compounds for inflammation and immune-related uses SYNTA PHARMACEUTICALS CORP. (US) 2007-11-29 US disclosed
US-20070275960-A1 Phenyl and pyridyl compounds for inflammation and immune-related uses SYNTA PHARMACEUTICALS CORP. (US) 2007-11-29 US disclosed
WO-2007087429-A2 PHENYL AND PYRIDYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2007-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275960-A1 Phenyl and pyridyl compounds for inflammation and immune-related uses NLRP3, CCR1, NLRP1 ABL1 3411/4885RAB9A 2515/4885DGAT1 4685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.